BioSpecifics Technologies Corporation Announces Additional Sales of Stock in Private Placement Offering
LYNBROOK, N.Y., June 10 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. today announced that it sold an aggregate of 100,000 unregistered shares of its common stock priced at $15 per share for aggregate proceeds to BioSpecifics of $1,500,000. The shares were purchased by certain private investors on June 9, 2008. The shares were sold in a company managed PIPE transaction at a premium over the market price.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications. It has a development and licensing agreement with Auxilium Pharmaceuticals, Inc. for clinical indications in Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive capsulitis).
CONTACT: Thomas L. Wegman, President of BioSpecifics Technologies Corp.,
Web site: http://www.biospecifics.com//